In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
In a boon for licensee Bristol Myers Squibb Co., Systimmune Inc.’s next-generation cancer drug, izalontamab brengitecan (iza-bren), hit both progression-free survival and overall survival endpoints in a phase III trial of Chinese patients with advanced triple-negative breast cancer.
Oncology-focused Eikon Therapeutics Inc. set the terms of its IPO Jan. 28, selling 17.648 million shares at a price range between $16 to $18 per share. At the top of the range, the Millbrae, Calif.-based biopharma company would raise about $317.7 million.
Researchers from Lanzhou University and Southern Medical University (China) have presented the discovery of a structurally distinct pyrimidine-based chemotype for the inhibition of KRAS G12C.
GAS41, the chromatin-associated protein encoded by YEATS4, is frequently overexpressed in non-small-cell lung cancer (NSCLC). Beyond its association with epigenetic dysregulation, GAS41 plays an active role in modulating transcriptional programs that are essential for NSCLC pathogenesis, underscoring its suitability as a mechanistically well-supported therapeutic target.
METTL3, the enzyme that adds the m6A RNA modification, is a key regulator of RNA processing and protein synthesis. In cancer, METTL3 is often overexpressed, driving tumor growth, invasion and therapy resistance across multiple malignancies, including lung, pancreatic, ovarian, colorectal cancers and acute myeloid leukemia.
Although tricomplex pan-RAS (ON) inhibitors, such as RMC-6236, constitute a promising class of therapeutics against RAS-driven cancers, their on-target, off-tumor toxicities challenge the dosing strategy and the safety of drug combinations.
The inhibition of PD-L1 and VEGF individually or in combination has shown efficacy across several solid tumor types, but not all patients respond to therapy or respond for short duration. IMM-2510 is a novel bispecific antibody developed by Immuneonco Biopharmaceuticals Inc. that targets both PD-L1 and VEGF, thus achieving both angiogenesis inhibition and immune checkpoint blockade.
Researchers from Chemdiv Inc. and Eilean Therapeutics LLC recently presented preclinical data on ZE77-0273, an AI-designed, reversible pan-EGFR inhibitor developed to address a key unmet need in the treatment of EGFR-mutant non-small-cell lung cancer.
